Advertisement
Clinical Outlook
-
Evolving biologic treatment options improving outcomes for patients with COPD
Farrukh Abbas, MD, FCCP, and Nicola Alexander Hanania, MD, MS, FCCP, explore the various treatment pathways—and the drugs targeting them—with the potential to reduce COPD exacerbations.
-
DPP-1 inhibitors enter clinical practice
Sunjay R. Devarajan, MD, FCCP, and Anas Hadeh, MD, FCCP, said DPP-1 inhibitors are expected to become a new standard of care, with ongoing studies further defining their role in noncystic fibrosis bronchiectasis management.
-
Biologic therapies in asthma: From foundation to the future
Biologic therapies are changing severe asthma management, shifting the goal from control to remission. Diego J. Maselli, MD, FCCP; Dharani Narendra, MD, FCCP; and Megan Conroy, MD, MAEd, FCCP, explore their impact in this installment of Clinical Outlook in Pulmonology.
-
-
-
